RIGL vs BCRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RIGL Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Rigel Pharmaceuticals Inc. (New) (RIGL) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while BCRX counters with relative strength in Valuation. Fundamentally, RIGL trades at 9.3x Forward P/E with 26.3% operating margin (+16.5% YoY revenue) versus BCRX at 8.9x Forward P/E and 48.8% operating margin (+13.1% YoY). In options structure, RIGL sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro) against BCRX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RIGL Revenue | BCRX Revenue | RIGL Op. Margin | BCRX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $40M | $20M | -163.3% | -456.2% | RIGL |
| FY2019 | $60M | $50M | -116.5% | -203.7% | RIGL |
| FY2020 | $110M | $20M | -26.7% | -981.1% | RIGL |
| FY2021 | $150M | $160M | -8.4% | -113.1% | RIGL |
| FY2022 | $120M | $270M | -46.2% | -54.8% | RIGL |
| FY2023 | $120M | $330M | -17.5% | -31.3% | RIGL |
| FY2024 | $180M | $450M | 13.5% | -0.6% | RIGL |
| FY2025 | $290M | $870M | 42.6% | 39.0% | RIGL |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RIGL | BCRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $860.3M | $1.9B | Larger Scale | BCRX |
| Trailing P/E Ratio Valuation | 2.8x | 13.0x | Lower Multiple | RIGL |
| Forward P/E Ratio Valuation | 9.3x | 8.9x | Lower Multiple | BCRX |
| Revenue Growth (YoY) Growth | +16.5% | +13.1% | Higher Growth | RIGL |
| Operating Margin (TTM) Profitability | 26.3% | 48.8% | Higher Margin | BCRX |
| Net Profit Margin Profitability | 106.6% | -37.4% | Higher Margin | RIGL |
| Return on Equity (ROE) Capital Efficiency | 109.2% | -1925.4% | Higher ROE | RIGL |
| 52-Week Range Position Momentum | 68% ($25โ$53) | 26% ($6โ$11) | Stronger Trend | RIGL |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 74% Vol | 0.77ฮฒ ยท 42% Vol | Lower Realized Risk | BCRX |
| Unified Institutional Score Composite Signal | 59.9 / 100 (HOLD) | 42.2 / 100 (HOLD) | Higher Composite | RIGL |